Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2016-08-28T10:08:44Z | - |
dc.date.available | 2016-08-28T10:08:44Z | - |
dc.date.issued | 2013 | * |
dc.identifier.issn | 0268-3369 | * |
dc.identifier.other | OAK-9941 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/223595 | - |
dc.description.abstract | The aims of this study were to investigate the outcomes of second salvage auto-SCT and to identify the impacts of a second auto-SCT compared with systemic chemotherapy alone on disease outcome. Data from 48 patients who underwent second auto-SCT were matched to 144 patients (1:3) who received systemic chemotherapy alone from the Korean Myeloma Registry. Groups were matched for nine potential prognostic factors and compared for treatment outcomes. The median age of matching-pairs at relapse was 55.5 years. A total of 156 patients (81%) received vincristine, doxorubicin and dexamethasone induction therapy before the first auto-SCT. Thirty-five patients (73%) in the second auto-SCT group received novel agent-based therapies before the second auto-SCT, and similar proportion in both groups received novel therapies after relapse of front-line auto-SCT. With a median follow-up of 55.3 months, patients who underwent a second auto-SCT had significantly better median OS (55.5 vs 25.4 months, P=0.035). In multivariate analysis for OS, <18 months time to progression after first auto-SCT, International Staging System III and salvage chemotherapy alone were independent predictors for worse OS. The outcomes of second auto-SCT appear to be superior to those of systemic chemotherapy alone. A randomized trial comparing both treatment strategies is required. © 2013 Macmillan Publishers Limited. All rights reserved. | * |
dc.language | English | * |
dc.title | Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 48 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 425 | * |
dc.relation.lastpage | 432 | * |
dc.relation.journaltitle | Bone Marrow Transplantation | * |
dc.identifier.doi | 10.1038/bmt.2012.164 | * |
dc.identifier.wosid | WOS:000316920100017 | * |
dc.identifier.scopusid | 2-s2.0-84875222958 | * |
dc.author.google | Yhim H.-Y. | * |
dc.author.google | Kim K. | * |
dc.author.google | Kim J.S. | * |
dc.author.google | Kang H.J. | * |
dc.author.google | Kim J.-A. | * |
dc.author.google | Min C.-K. | * |
dc.author.google | Bae S.H. | * |
dc.author.google | Park E. | * |
dc.author.google | Yang D.-H. | * |
dc.author.google | Suh C. | * |
dc.author.google | Kim M.K. | * |
dc.author.google | Mun Y.-C. | * |
dc.author.google | Eom H.S. | * |
dc.author.google | Shin H.J. | * |
dc.author.google | Yoon H.-J. | * |
dc.author.google | Kwon J.H. | * |
dc.author.google | Lee J.H. | * |
dc.author.google | Kim Y.S. | * |
dc.author.google | Yoon S.-S. | * |
dc.author.google | Kwak J.-Y. | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |